Specific Bacterial Species and Metabolite That Improves Immune Checkpoint Inhibitor Therapy Efficacy
US-2020129570-A1 · Apr 30, 2020 · US
Antitumor effect potentiator
US12186350B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12186350-B2 |
| Application number | US-201917279322-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 25, 2019 |
| Priority date | Sep 25, 2018 |
| Publication date | Jan 7, 2025 |
| Grant date | Jan 7, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for potentiating an antitumor effect of an immune checkpoint inhibitor, the method comprising: administering an effective amount of a probiotic, a prebiotic, and an immune checkpoint inhibitor to a subject in need thereof, wherein the probiotic comprises Lactobacillus casei YIT9029 (FERM BP-1366) and Bifidobacterium breve YIT12272 (FERM BP-11320), the prebiotic is a galactooligosaccharide, and the immune checkpoint inhibitor is an anti-PD-1 antibody. 2. The method of claim 1 , wherein a content ratio of the probiotic to the prebiotic is from 0.01×10 11 to 20×10 11 CFU to 1 g of the total mass of the prebiotic.
Assignees
Inventors
Classifications
against B7 molecules, e.g. CD80, CD86 · CPC title
against CD28 or CD152 · CPC title
Probiotics · CPC title
Bifidobacteria · CPC title
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12186350B2 cover?
- An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.
- Who is the assignee on this patent?
- Nat Cerebral & Cardiovascular Ct, Yakult Honsha Kk
- What technology area does this patent fall under?
- Primary CPC classification A61K35/747. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).